CompletedPhase 3NCT02683889
Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation
Studying Hereditary steroid-resistant nephrotic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Colorado, Denver
- Principal Investigator
- Sixto Giusti, MD, M.DUniversity of Colorado, Denver
- Intervention
- Acthar(drug)
- Enrollment
- 15 target
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2019 – 2024
Study locations (1)
- Medstar Georgetown Transplant Institute, Washington D.C., District of Columbia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02683889 on ClinicalTrials.govOther trials for Hereditary steroid-resistant nephrotic syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06635720REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE)The Hospital for Sick Children
- RECRUITINGNCT06334692Autoantibodies Against-nephrin in Idiopathic Nephrotic SyndromeMario Negri Institute for Pharmacological Research
- RECRUITINGNCT06162546ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and BiobankChristoph Aufricht
- RECRUITINGPHASE3NCT05183646A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARBDimerix Bioscience Pty Ltd
- RECRUITINGNCT01605266INSIGHT (Insight Into Nephrotic Syndrome)The Hospital for Sick Children
See all trials for Hereditary steroid-resistant nephrotic syndrome →